Anti-COVID-19 Vaccination in Patients with Autoimmune-Autoinflammatory Disorders and Primary/Secondary Immunodeficiencies: The Position of the Task Force on Behalf of the Italian Immunological Societies
暂无分享,去创建一个
P. Migliorini | M. Cassatella | A. Vacca | R. Nisini | B. Laganà | V. Racanelli | E. Maggi | C. Lunardi | R. Asero | I. Quinti | G. Senna | P. Parronchi | R. D'Amelio
[1] C. von Kalle,et al. Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study , 2021, The Lancet Respiratory Medicine.
[2] R. Myers,et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant , 2021, The New England journal of medicine.
[3] U. Stervbo,et al. Correspondence on ‘SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response’ , 2021, Annals of the Rheumatic Diseases.
[4] J. Klingström,et al. Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination , 2021, The New England journal of medicine.
[5] A. Yılmaz,et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey , 2021, The Lancet.
[6] P. Kalra,et al. Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine , 2021, The New England journal of medicine.
[7] L. Cooper,et al. Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military. , 2021, JAMA cardiology.
[8] S. Zaffina,et al. SARS-CoV-2 Vaccine Induced Atypical Immune Responses in Antibody Defects: Everybody Does their Best , 2021, Journal of Clinical Immunology.
[9] G. Burmester,et al. Successful BNT162b2 booster vaccinations in a patient with rheumatoid arthritis and initially negative antibody response , 2021, Annals of the Rheumatic Diseases.
[10] J. Izopet,et al. Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients , 2021, The New England journal of medicine.
[11] H. Ulmer,et al. The Safety and Immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 Vaccine in Hemodialysis Patients , 2021, Frontiers in Immunology.
[12] Andrew T. Kroger,et al. American College of Rheumatology Guidance for COVID‐19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 2 , 2021, Arthritis & rheumatology.
[13] C. Rice,et al. Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection , 2021, Nature.
[14] G. Debnath,et al. Antibody Responses to SARS-CoV-2 mRNA Vaccines Are Detectable in Saliva , 2021, Pathogens & immunity.
[15] K. Pradhan,et al. Seroconversion rates following COVID-19 vaccination among patients with cancer , 2021, Cancer Cell.
[16] Andrew L. Phillips,et al. Prevention and Attenuation of COVID-19 by BNT162b2 and mRNA-1273 Vaccines , 2021, medRxiv.
[17] G. Shefer,et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study , 2021, Annals of the Rheumatic Diseases.
[18] A. Sheikh,et al. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness , 2021, The Lancet.
[19] N. Freund,et al. Immunogenicity of Pfizer-BioNTech COVID-19 vaccine in patients with inborn errors of immunity , 2021, Journal of Allergy and Clinical Immunology.
[20] F. Kirchhoff,et al. Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity , 2021, medRxiv.
[21] Changgui Li,et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial , 2021, The Lancet Infectious Diseases.
[22] A. Gaggioli,et al. Detection of antibodies against SARS-CoV-2 both in plasma pools for fractionation and in commercial intravenous immunoglobulins produced from plasma collected in Italy during the pandemic. , 2021, Blood transfusion = Trasfusione del sangue.
[23] P. Dormitzer,et al. Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents , 2021, The New England journal of medicine.
[24] M. Neurath,et al. Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease , 2021, Annals of the Rheumatic Diseases.
[25] D. Segev,et al. High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases , 2021, Annals of the Rheumatic Diseases.
[26] A. Joshi,et al. Seroconversion after coronavirus disease 2019 vaccination in patients with immune deficiency , 2021, Annals of Allergy, Asthma & Immunology.
[27] E. Callaway. Mix-and-match COVID vaccines trigger potent immune response , 2021, Nature.
[28] G. Aurigemma,et al. Myocarditis following COVID-19 vaccination , 2021, Radiology Case Reports.
[29] P. Kalra,et al. Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.1.7 Variant , 2021, medRxiv.
[30] G. Alter,et al. Immunogenicity of COVID-19 mRNA Vaccines in Pregnant and Lactating Women. , 2021, JAMA.
[31] M. Snape,et al. Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data , 2021, The Lancet.
[32] D. Jannat-Khah,et al. Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS- CoV-2 vaccination in patients with rheumatic diseases , 2021, Annals of the Rheumatic Diseases.
[33] L. Piemonti,et al. Neutralizing antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for survival , 2021, Nature Communications.
[34] H. Haslacher,et al. SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response , 2021, Annals of the Rheumatic Diseases.
[35] C. Berking,et al. SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases , 2021, Annals of the Rheumatic Diseases.
[36] L. Abu-Raddad,et al. Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants , 2021, The New England journal of medicine.
[37] D. Segev,et al. Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients. , 2021, JAMA.
[38] L. Cosmi,et al. First-dose mRNA vaccination is sufficient to reactivate immunological memory to SARS-CoV-2 in recovered COVID-19 subjects. , 2021, The Journal of clinical investigation.
[39] J. Szer,et al. COVID‐19 vaccination in haematology patients: an Australian and New Zealand consensus position statement , 2021, Internal medicine journal.
[40] E. Woo,et al. US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021. , 2021, JAMA.
[41] M. Malim,et al. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study , 2021, The Lancet Oncology.
[42] H. Fennema,et al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 , 2021, The New England journal of medicine.
[43] C. Olson,et al. Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons , 2021, The New England journal of medicine.
[44] D. Goldblatt,et al. Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination , 2021, The New England journal of medicine.
[45] E. Clementi,et al. How to Manage COVID-19 Vaccination in Immune-Mediated Inflammatory Diseases: An Expert Opinion by IMIDs Study Group , 2021, Frontiers in Immunology.
[46] M. Suchard,et al. Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil , 2021, Science.
[47] D. Rimar,et al. Herpes zoster following BNT162b2 mRNA Covid-19 vaccination in patients with autoimmune inflammatory rheumatic diseases: a case series , 2021, Rheumatology.
[48] I. Youngster,et al. SARS-CoV-2-Specific Antibodies in Breast Milk After COVID-19 Vaccination of Breastfeeding Women. , 2021, JAMA.
[49] Gregory F. Wu,et al. Glucocorticoids and B Cell Depleting Agents Substantially Impair Immunogenicity of mRNA Vaccines to SARS-CoV-2 , 2021, medRxiv.
[50] C. Conrad,et al. Impaired Humoral and Cellular Immunity after SARS-CoV2 BNT162b2 (Tozinameran) Prime-Boost Vaccination in Kidney Transplant Recipients , 2021, medRxiv.
[51] J. Blankson,et al. SARS-CoV-2 mRNA vaccines induce broad CD4+ T cell responses that recognize SARS-CoV-2 variants and HCoV-NL63. , 2021, The Journal of clinical investigation.
[52] D. Stuart,et al. Antibody evasion by the P.1 strain of SARS-CoV-2 , 2021, Cell.
[53] L. Stamatatos,et al. mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection , 2021, Science.
[54] E. Lee,et al. COVID-19 Vaccination in Patients with Autoimmune Inflammatory Rheumatic Diseases: Clinical Guidance of the Korean College of Rheumatology , 2021, Journal of Korean medical science.
[55] P. Hoff,et al. Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort , 2021, Annals of the Rheumatic Diseases.
[56] D. Segev,et al. Safety of the first dose of mRNA SARS-CoV-2 vaccines in patients with rheumatic and musculoskeletal diseases , 2021, Annals of the Rheumatic Diseases.
[57] R. Rubin. COVID-19 Vaccines vs Variants-Determining How Much Immunity Is Enough. , 2021, JAMA.
[58] N. Sullivan,et al. Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine , 2021, The New England journal of medicine.
[59] S. Madhi,et al. ChAdOx1 nCoV-19 (AZD1222) Covid-19 vaccine efficacy against the B.1.351 variant , 2021, The New England Journal of Medicine.
[60] William T. Harvey,et al. Author Correction: Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies , 2021, Nature.
[61] Ahmed Abdul Azim,et al. Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19. , 2021, JAMA.
[62] K. Ella,et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial , 2021, The Lancet Infectious Diseases.
[63] P. Dormitzer,et al. Neutralizing Activity of BNT162b2-Elicited Serum , 2021, The New England journal of medicine.
[64] Carl A. B. Pearson,et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England , 2021, Science.
[65] K. Agarwal,et al. Immunogenicity and protective efficacy of inactivated SARS-CoV-2 vaccine candidate, BBV152 in rhesus macaques , 2021, Nature Communications.
[66] Eun-Ju Lee,et al. Thrombocytopenia following Pfizer and Moderna SARS‐CoV‐2 vaccination , 2021, American journal of hematology.
[67] J. Bijlsma. EULAR December 2020 viewpoints on SARS-CoV-2 vaccination in patients with RMDs , 2021, Annals of the Rheumatic Diseases.
[68] Naomi R. Waterlow,et al. Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7 , 2021, Nature.
[69] V. Gushchin,et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia , 2021, The Lancet.
[70] P. McKay,et al. Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice , 2021, Nature Communications.
[71] I. Quinti,et al. Clinical management of patients with primary immunodeficiencies during the COVID-19 pandemic , 2021, Expert review of clinical immunology.
[72] I. Donatelli,et al. Immunogenicity of Viral Vaccines in the Italian Military , 2021, Biomedicines.
[73] Jialu Zhang,et al. Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates , 2021, Emerging microbes & infections.
[74] J. Mascola,et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine , 2020, The New England journal of medicine.
[75] E. Phillips,et al. Maintaining Safety with SARS-CoV-2 Vaccines , 2020, The New England journal of medicine.
[76] Smita Y. Patel,et al. COVID-19 in patients with primary and secondary immunodeficiency: The United Kingdom experience , 2020, Journal of Allergy and Clinical Immunology.
[77] P. Dormitzer,et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020, The New England journal of medicine.
[78] Nguyen H. Tran,et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK , 2020, Lancet.
[79] C. Rice,et al. Enhanced SARS-CoV-2 neutralization by dimeric IgA , 2020, Science Translational Medicine.
[80] A. Druyan,et al. The risk for severe COVID 19 in patients with autoimmune and/or inflammatory diseases: First wave lessons , 2020, Dermatologic therapy.
[81] Nguyen H. Tran,et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. , 2020, Lancet.
[82] K. Chu,et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial , 2020, The Lancet Infectious Diseases.
[83] Gaurav D. Gaiha,et al. Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host , 2020, The New England journal of medicine.
[84] D. Micic,et al. Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis , 2020, Annals of the Rheumatic Diseases.
[85] B. Lambrecht,et al. Coronavirus disease 2019 in patients with inborn errors of immunity: An international study , 2020, Journal of Allergy and Clinical Immunology.
[86] J. Tregoning,et al. Vaccines for COVID‐19 , 2020, Clinical and experimental immunology.
[87] A. Gintsburg,et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia , 2020, The Lancet.
[88] V. Shinde,et al. Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine , 2020, The New England journal of medicine.
[89] N. Patel,et al. NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge , 2020, bioRxiv.
[90] V. Munster,et al. ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques , 2020, Nature.
[91] Rebecca J. Loomis,et al. Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates , 2020, The New England journal of medicine.
[92] Matthew S. Miller,et al. Cross-sectional evaluation of humoral responses against SARS-CoV-2 Spike , 2020, bioRxiv.
[93] Y. Hu,et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial , 2020, The Lancet.
[94] R. Gajardo,et al. Currently available intravenous immunoglobulin contains antibodies reacting against severe acute respiratory syndrome coronavirus 2 antigens , 2020, Immunotherapy.
[95] V. Lougaris,et al. A possible role for B cells in COVID-19? Lesson from patients with agammaglobulinemia , 2020, Journal of Allergy and Clinical Immunology.
[96] S. Antinori,et al. COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome? , 2020, Clinical and experimental rheumatology.
[97] John Hodgson,et al. The pandemic pipeline , 2020, Nature Biotechnology.
[98] M. Dougados,et al. Efficacy, immunogenicity and safety of vaccination in adult patients with autoimmune inflammatory rheumatic diseases: a systematic literature review for the 2019 update of EULAR recommendations , 2019, RMD Open.
[99] M. Dougados,et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases , 2019, Annals of the rheumatic diseases.
[100] A. Winkelmann,et al. Vaccination in Multiple Sclerosis: Friend or Foe? , 2019, Front. Immunol..
[101] Stig Egil Bojesen,et al. Lymphopenia and risk of infection and infection-related death in 98,344 individuals from a prospective Danish population-based study , 2018, PLoS medicine.
[102] G. Valesini,et al. Anti-polysaccharide and anti-diphtheria protective antibodies after 13-valent pneumococcal conjugate vaccination in rheumatoid arthritis patients under immunosuppressive therapy. , 2018, Clinical immunology.
[103] H. Herfarth,et al. Vaccinations in Adult Patients with Inflammatory Bowel Diseases in the West , 2018, Inflammatory Intestinal Diseases.
[104] V. Gallo,et al. Vaccination in immunocompromised host: Recommendations of Italian Primary Immunodeficiency Network Centers (IPINET). , 2018, Vaccine.
[105] A. Guffroy,et al. [Systemic lupus erythematosus and lymphopenia: Clinical and pathophysiological features]. , 2017, La Revue de medecine interne.
[106] S. Bühler,et al. Safety of live vaccinations on immunosuppressive therapy in patients with immune-mediated inflammatory diseases, solid organ transplantation or after bone-marrow transplantation - A systematic review of randomized trials, observational studies and case reports. , 2017, Vaccine.
[107] A. Bertoletti,et al. Memory T cell responses targeting the SARS coronavirus persist up to 11 years post-infection , 2016, Vaccine.
[108] A. Bolhassani,et al. Prime-boost vaccine strategy against viral infections: Mechanisms and benefits. , 2016, Vaccine.
[109] L. Carli,et al. Leukopenia, lymphopenia, and neutropenia in systemic lupus erythematosus: Prevalence and clinical impact--A systematic literature review. , 2015, Seminars in arthritis and rheumatism.
[110] M. Eibl,et al. Vaccination in patients with primary immune deficiency, secondary immune deficiency and autoimmunity with immune regulatory abnormalities. , 2015, Immunotherapy.
[111] M. Cattaruzza,et al. Infection risk in Rheumatoid Arthritis and Spondyloarthropathy patients under treatment with DMARDs, Corticosteroids and TNF-α antagonists , 2014, Journal of Translational Medicine.
[112] A. Bousvaros,et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[113] E. Mendelson,et al. The cellular immune response to influenza vaccination is preserved in rheumatoid arthritis patients treated with rituximab. , 2011, Vaccine.
[114] S. Salemi,et al. Are Anti-Infectious Vaccinations Safe and Effective in Patients with Autoimmunity? , 2010, International reviews of immunology.
[115] R. Koup,et al. Persistent memory CD4+ and CD8+ T-cell responses in recovered severe acute respiratory syndrome (SARS) patients to SARS coronavirus M antigen. , 2007, The Journal of general virology.
[116] Marrow Transplantation. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients , 2000, Biology of Blood and Marrow Transplantation.
[117] R. Meidan,et al. LB0003 IMMUNOGENICITY AND SAFETY OF THE BNT162b2 mRNA COVID-19 VACCINE IN ADULT PATIENTS WITH AUTOIMMUNE INFLAMMATORY RHEUMATIC DISEASES AND GENERAL POPULATION: A MULTICENTER STUDY , 2021, Annals of the Rheumatic Diseases.
[118] L. Leibovici,et al. Influenza vaccines in immunosuppressed adults with cancer. , 2018, The Cochrane database of systematic reviews.
[119] M. A. Meledeo,et al. Recent advances in use of fresh frozen plasma, cryoprecipitate, immunoglobulins, and clotting factors for transfusion support in patients with hematologic disease , 2020, Seminars in Hematology.